I agree with your remarks re criticism of management. Dont agree with your comments re disingenuous comments when reporting 100% CR for AML. Reality is CORE NK CASE WESTERN trial is a basket trial to identify which solid and blood cancers respond best to the combo therapy.
Importantly, during Phase 1 Dose Finding, there was another (durable) Complete Response for an MDS patient. MDS often leads into an AML diagnosis.
So we have 2 CRs in this space in a very small sample.
Now if you refer to"Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial", they had 5 CRs (3 durable > 10mths) out of 59 patients, and that drug has been awarded Fast Track Designation from the FDA.
So we are actually in the territory of breakthrough designation from the FDA already! If we see similar results in the CORE NK MD Anderson Trial (with a different combo and patient profile) then the world will sit up and take notice!
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)